Trial Profile

Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study of OPL-002 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tamuzimod (Primary)
Indications Inflammatory bowel diseases
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

23 Jun 2020 Status changed from recruiting to completed, according to an Oppilan Pharma media release.
23 Jun 2020 According to an Oppilan Pharma media release, top-line results from this study were recently presented at the Digestive Disease Week (DDW) 2020 Virtual Scientific Program.
23 Jun 2020 Top-line results from this study presented in an Oppilan Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com